Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II)

被引:8
|
作者
Legrand, Victor M. [2 ]
Garg, Scot [1 ]
Serruys, Patrick W. [1 ]
Virtanen, Kari S. [3 ]
Szurawitzki, Guenter [4 ]
Voudris, Vassilis [5 ]
Fontanelli, Alessandro [6 ]
Endersen, Knut [7 ]
Kranjec, Igor [8 ]
Rademaker, Tessa [9 ]
Stefanidis, Christodoulos I. [10 ]
Wittebols, Kristel [11 ]
机构
[1] Erasmus MC, Thoraxctr, NL-3015 GD Rotterdam, Netherlands
[2] CHU Sart Tilman, B-4000 Liege, Belgium
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
[4] Elisabeth Hosp, Essen, Germany
[5] Onassis Cardiac Surg Ctr, Athens, Greece
[6] San Bortolo Hosp, Vicenza, Italy
[7] Riskhosp, Oslo, Norway
[8] Clin Ctr Ljubljana, Ljubljana, Slovenia
[9] Cardialysis BV, Rotterdam, Netherlands
[10] Hippokrateion Hosp, Athens, Greece
[11] Johnson & Johnson Co, Cordis, Waterloo, Belgium
关键词
Ageing; coronary artery disease; revascularisation; bare metal stents; sirolimus-eluting stents; surgery; GREATER-THAN-OR-EQUAL-TO-80; YEARS; DIABETES-MELLITUS; ELDERLY-PATIENTS; CARDIAC-SURGERY; FOLLOW-UP; INTERVENTION; DISEASE; MORTALITY; EUROSCORE; STRATEGY;
D O I
10.4244/EIJV6I7A144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial Revascularisation Therapies Study (ARTS) part land part II. The potential influence of age in determining the most appropriate revascularisation strategy for patients with MVD is largely unknown. Methods and results: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent (BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG (p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent predictor of MACCE among PCI treated patients (p<0.02), but didn't affect three-year outcomes following CABG. Conclusions: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients. The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the most important predictor of MACCE following PCI.
引用
收藏
页码:838 / 845
页数:8
相关论文
共 27 条
  • [21] A Randomized Comparison of The Second Generation Biodegradable Polymer Sirolimus-eluting Stent (EXCEL-II) and The First Generation EXCEL-I stent in Patients with De novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial
    Han, Yaling
    Yang, Yuejin
    Xu, Bo
    Sun, Yong
    Yuan, Zuyi
    Wang, Haichang
    Liu, Jinghua
    Liu, Huiliang
    Ma, Genshan
    Wang, Geng
    Jing, Quanmin
    Wang, Xiaozeng
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B28 - B28
  • [22] The european multicenter, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (E-SIRIUS): 4-year clinical outcomes
    Schofer, J.
    Breithardt, G.
    Garcia, E.
    Gershlick, A.
    Schlueter, M.
    Wichter, T.
    Wijns, W.
    EUROPEAN HEART JOURNAL, 2006, 27 : 829 - 829
  • [23] The European Multicenter, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with De Novo Coronary Artery Lesions (E-SIRIUS): 5-Year Clinical Outcomes
    Kelbaek, H.
    Simon, R.
    Rubino, P.
    Legrand, V.
    Guagliumi, G.
    Reimers, B.
    Taeymans, I.
    Van den Branden, F.
    Breithardt, G.
    Schofer, J.
    EUROPEAN HEART JOURNAL, 2007, 28 : 329 - 329
  • [24] The European multicenter, randomized, double-blind study of the Sirolimus-eluting Stent in the treatment of patients with de novo coronary artery lesions: 5-year clinical outcomes of the E-SIRIUS TRIAL
    Kelbaek, Henning
    Schampoert, Erick
    Simon, Ruediger
    Rubino, Paolo
    Legrand, Victor
    Guagliumi, Giulio
    Reimers, Bernard
    Taeymans, Yves
    Van den Branden, Frank
    Wittebols, Kristel
    Stoll, Hans-Peter
    Breithardt, Guenther
    Schofer, Joachim
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (8A): : 35L - 35L
  • [25] Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
    Xu, Bo
    Gao, Run-Lin
    Lansky, Alexandra
    Yang, Yuejin
    Ma Changsheng
    Han, Yaling
    Chen, Shao Liang
    Li, Hui
    Zhang, Ruiyan
    Fu, Guosheng
    Yuan, Zuyi
    Huo, Yong
    Li, Wei
    Zhao, Yelin
    Leon, Martin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B7 - B8
  • [26] Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial
    Xu, Bo
    Dou, Kefei
    Yang, Yuejin
    Lv, Shuzheng
    Wang, Lefeng
    Wang, Haichang
    Li, Zhanquan
    Wang, Lei
    Chen, Yundai
    Huo, Yong
    Li, Wei
    Kirtane, Ajay J.
    Gao, Runlin
    EUROINTERVENTION, 2012, 8 (07) : 796 - 802